Literature DB >> 28643861

Challenges in the Development of Novel Cardiovascular Therapies.

T J Hwang1, A S Kesselheim1.   

Abstract

Cardiovascular disease accounts for nearly one in three deaths globally, but few novel therapies have reached patients and clinicians in recent years. This translational report reviews trends in the development and approval of cardiovascular drugs and evaluates recent innovation in the field of cardiovascular disease therapeutics. New policies are needed to better support the development of safe and effective therapies with the greatest potential to improve patient health outcomes.
© 2017 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28643861     DOI: 10.1002/cpt.703

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  3 in total

1.  Multicellular Human Cardiac Organoids Transcriptomically Model Distinct Tissue-Level Features of Adult Myocardium.

Authors:  Charles M Kerr; Dylan Richards; Donald R Menick; Kristine Y Deleon-Pennell; Ying Mei
Journal:  Int J Mol Sci       Date:  2021-08-06       Impact factor: 6.208

2.  Overcoming the Declining Trends in Innovation and Investment in Cardiovascular Therapeutics: Beyond EROOM's Law.

Authors:  Gail A Van Norman
Journal:  JACC Basic Transl Sci       Date:  2017-10-30

3.  Pirfenidone Has Anti-fibrotic Effects in a Tissue-Engineered Model of Human Cardiac Fibrosis.

Authors:  Thomas C L Bracco Gartner; Sandra Crnko; Laurynas Leiteris; Iris van Adrichem; Linda W van Laake; Carlijn V C Bouten; Marie José Goumans; Willem J L Suyker; Joost P G Sluijter; Jesper Hjortnaes
Journal:  Front Cardiovasc Med       Date:  2022-03-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.